Saniona — Share Issue/Capital Change 2024

Dec 30, 2024

PRESS RELEASE

30 December 2024 08:00:00 CET

Change in number of shares and votes in Saniona AB

During the month of December, the registered number of shares and votes in Saniona AB ("Saniona") has increased due to conversion of outstanding convertibles issued by Saniona to Fenja Capital II A/S on 15 February 2024. As of 30 December 2024, the registered number of shares and votes in Saniona amounts to 112,532,750.

For more information, please contact

Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com

About Saniona

Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of epilepsy and other neurological disorders. Saniona's epilepsy pipeline includes SAN2219, targeting acute repetitive seizures; and SAN2355, addressing refractory focal onset seizures. Beyond epilepsy, Saniona oversees four clinical programs poised for collaboration. Tesofensine for obesity is Saniona's most advanced candidate and is out licensed to Medix in Mexico and Argentina. Tesomet™ is ready for Phase 2b, targeting rare eating disorders, while SAN903 is ready for Phase 1 for inflammatory bowel disease and SAN2465 is set for preclinical development for major depressive disorder. Saniona partners include Acadia Pharmaceuticals, Boehringer Ingelheim GmbH, Productos Medix S.A de S.V, AstronauTx Limited, and Cephagenix ApS. Saniona is based in Copenhagen and listed on Nasdaq Stockholm Main Market.

For more information, visit www.saniona.com.

This information is information that Saniona AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-12-30 08:00 CET.

Attachments Change in number of shares and votes in Saniona AB